Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Work In Process (2019 - 2025)

Protalix BioTherapeutics (PLX) has 8 years of Work In Process data on record, last reported at $5.4 million in Q3 2025.

  • For Q3 2025, Work In Process fell 56.29% year-over-year to $5.4 million; the TTM value through Sep 2025 reached $5.4 million, down 56.29%, while the annual FY2024 figure was $11.2 million, 24.19% up from the prior year.
  • Work In Process reached $5.4 million in Q3 2025 per PLX's latest filing, down from $8.1 million in the prior quarter.
  • Across five years, Work In Process topped out at $12.3 million in Q3 2024 and bottomed at $1.5 million in Q1 2023.
  • Average Work In Process over 5 years is $5.9 million, with a median of $3.5 million recorded in 2021.
  • Peak YoY movement for Work In Process: skyrocketed 498.11% in 2024, then plummeted 56.29% in 2025.
  • A 5-year view of Work In Process shows it stood at $3.3 million in 2021, then dropped by 17.9% to $2.7 million in 2022, then surged by 238.13% to $9.1 million in 2023, then grew by 24.19% to $11.2 million in 2024, then crashed by 52.38% to $5.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $5.4 million in Q3 2025, $8.1 million in Q2 2025, and $8.0 million in Q1 2025.